目的 探討鹽酸魯拉西酮片聯(lián)合舒必利片治療精神分裂癥的臨床療效。方法 選取2020年2月-2022年11月在上海市靜安區(qū)精神衛(wèi)生中心就診的120例精神分裂癥患者,按照計(jì)算機(jī)隨機(jī)排列法分為對照組和治療組,每組各60例。對照組患者口服舒必利片,首次劑量1片/次,3次/d,治療7 d后增加至3片/次,3次/d。治療組患者在對照組基礎(chǔ)上口服鹽酸魯拉西酮片,1片/次,1次/d。兩組患者連續(xù)治療2個(gè)月。觀察兩組的臨床療效,比較兩組的陽性與陰性癥狀量表(PANSS)評(píng)分、精神分裂癥生活質(zhì)量量表(SQLS)評(píng)分以及血清中催乳素(PRL)、白細(xì)胞介素-6(IL-6)、白細(xì)胞介素-17(IL-17)水平。結(jié)果 治療后,治療組的總有效率為91.67%,對照組的總有效率為78.33%,組間比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組的PANSS各項(xiàng)評(píng)分均顯著降低(P<0.05),且治療組PANSS各項(xiàng)評(píng)分較對照組更低(P<0.05)。治療后,兩組的SQLS各項(xiàng)評(píng)分顯著降低(P<0.05),治療組SQLS各項(xiàng)評(píng)分降低程度高于對照組(P<0.05)。治療后,兩組的血清PRL水平高于治療前,血清IL-6、IL-17水平低于治療前(P<0.05);治療后,治療組的血清IL-6、IL-17水平低于對照組(P<0.05)。結(jié)論 鹽酸魯拉西酮片聯(lián)合舒必利片可提高精神分裂癥的臨床療效,減輕患者精神癥狀,提高生活質(zhì)量,減輕炎癥反應(yīng),且藥物安全性良好。

Objective To investigate the clinical effect of Lurasidone Hydrochloride Tablets combined with Sulpiride Tablets in treatment of schizophrenia. Methods Patients (120 cases) with schizophrenia in Shanghai Jing'an District Mental Health Center from February 2020 to November 2022 were divided into control and treatment groups according to the computer random arrangement method, and each group had 60 cases. Patients in the control group were po administered with Sulpiride Tablets, initial dose of 1 tablet/time, three times daily. After 7 d of treatment, the dose was increased to 3 tablets/time, three times daily. Patients in the treatment group were po administered with Lurasidone Hydrochloride Tablets on the basis of the control group, 1 tablet/time, once daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and PANSS scores, SQLS scores, the serum levels of PRL, IL-6, and IL-17 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.67%, while the total effective rate of the control group was 78.33%, and there was a statistically significant difference between the groups (P < 0.05). After treatment, the scoring of each item in PANSS of two groups were significantly reduced (P < 0.05), and the scoring of each item in PANSS of the treatment group were lower than those of the control group (P < 0.05). After treatment, the scoring of each item in SQLS of two groups were significantly decreased (P < 0.05), and the scoring of each item in SQLS in the treatment group was higher than that in the control group (P < 0.05). After treatment, the serum levels of PRL in two groups were higher than before treatment, while the serum levels of IL-6 and IL-17 were lower than before treatment (P < 0.05). After treatment, the serum levels of IL-6 and IL-17 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Lurasidone Hydrochloride Tablets combined with Sulpiride Tablets can improve the efficacy of schizophrenia, further reduce the psychiatric symptoms, improve the quality of life, alleviate inflammatory reactions, with good drug safety.

R971

上海市靜安區(qū)精神衛(wèi)生中心醫(yī)學(xué)科研課題(2019KY04)